Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. Hicks D, O'Regan RM. J Clin Oncol 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hicks D, O'Regan RM. Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition. J Clin Oncol 2022 Feb 24:JCO2102850. doi: 10.1200/JCO.21.02850.
PMID: 35201844